Abstract
Purpose
We investigated the clinical role of F-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in the identification of the primary site and the selection of the optimal biopsy site in patients with suspected bone metastasis of unknown primary site.
Methods
The patients with suspected bone metastasis who underwent PET-CT for evaluation of primary site were enrolled in this study. The primary sites were identified by the histopathologic or imaging studies and were classified according to the FDG uptake positivity of the primary site. To evaluate the guiding capability of PET-CT in biopsy site selection, we statistically analyzed whether the biopsy site could be affected according to the presence of extra-skeletal FDG uptake.
Results
Among 74 enrolled patients, 51 patients had a metastatic bone disease. The primary site was identified in 48 of 51 patients (94.1%). Forty-six patients were eligible to test the association of clinical choice of biopsy site with PET positivity of extra-skeletal lesion. The extra-skeletal biopsies were done in 42 out of 43 patients with positive extra-skeletal uptake lesions. Bone biopsies were inevitably performed in the other three patients without extra-skeletal uptake lesions. The association came out to be significant (Fisher’s exact test, P < 0.001).
Conclusion
F-18 FDG PET-CT significantly contributed not only to identify the primary site but also to suggest optimal biopsy sites in patients with suspected bone metastasis.
References
Disibio G, French SW. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008;132:931–9.
Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz JK, Denkert C, et al. The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2015;6:570–83.
Katagiri H, Takahashi M, Inagaki J, Sugiura H, Ito S, Iwata H. Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: a retrospective study. Cancer. 1999;86:533–7.
Ibrahim T, Mercatali L, Amadori D. Bone and cancer: the osteoncology. Clin Cases Miner Bone Metab. 2013;10:121–3.
Taylor MB, Bromham NR, Arnold SE. Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines. Br J Radiol. 2012;85:661–71.
Cardella JF, Bakal CW, Bertino RE, Burke DR, Drooz A, Haskal Z, et al. Quality improvement guidelines for image-guided percutaneous biopsy in adults. J Vasc Interv Radiol. 2003;14:S227–30.
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.
Park SB, Park JM, Moon SH, Cho YS, Sun JM, Kim BT, et al. Role of 18F-FDG PET/CT in patients without known primary malignancy with skeletal lesions suspicious for cancer metastasis. PLoS One. 2018;13:e0196808.
Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009;19:731–44.
Burglin SA, Hess S, Hoilund-Carlsen PF, Gerke O. 18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e6713.
Koc ZP, Kara PO, Dagtekin A. Detection of unknown primary tumor in patients presented with brain metastasis by F-18 fluorodeoxyglucose positron emission tomography/computed tomography. CNS Oncol. 2018;7:CNS12.
Cengiz A, Goksel S, Yurekli Y. Diagnostic value of (18)F-FDG PET/CT in patients with carcinoma of unknown primary. Mol Imaging Radionucl Ther. 2018;27:126–32.
Noij DP, Martens RM, Zwezerijnen B, Koopman T, de Bree R, Hoekstra OS, et al. Diagnostic value of diffusion-weighted imaging and (18)F-FDG-PET/CT for the detection of unknown primary head and neck cancer in patients presenting with cervical metastasis. Eur J Radiol. 2018;107:20–5.
Fei B, Schuster DM. PET molecular imaging-directed biopsy: a review. AJR Am J Roentgenol. 2017;209:255–69.
Purandare NC, Kulkarni AV, Kulkarni SS, Roy D, Agrawal A, Shah S, et al. 18F-FDG PET/CT-directed biopsy: does it offer incremental benefit? Nucl Med Commun. 2013;34:203–10.
Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003;23:315–40 quiz 533.
Hofman MS, Hicks RJ. How we read oncologic FDG PET/CT. Cancer Imaging. 2016;16:35.
Rahman WT, Wale DJ, Viglianti BL, Townsend DM, Manganaro MS, Gross MD, et al. The impact of infection and inflammation in oncologic (18)F-FDG PET/CT imaging. Biomed Pharmacother. 2019;117:109168.
Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61–77 quiz 150-1.
Li Y, Wang T, Fu YF, Shi YB, Wang JY. Computed tomography-guided biopsy for sub-centimetre lung nodules: technical success and diagnostic accuracy. Clin Respir J. 2020.
Hu X, Yang ZQ, Shao YX, Dou WC, Xiong SC, Yang WX, et al. MRI-targeted biopsy versus standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis of randomized controlled trials. Abdom Radiol (NY). 2020.
Kim SY, Chung HW, Oh TS, Lee JS. Practical guidelines for ultrasound-guided core needle biopsy of soft-tissue lesions: transformation from beginner to specialist. Korean J Radiol. 2017;18:361–9.
Huang AJ, Kattapuram SV. Musculoskeletal neoplasms: biopsy and intervention. Radiol Clin N Am. 2011;49:1287–305 vii.
Shif Y, Kung JW, McMahon CJ, Mhuircheartaigh JN, Lin YC, Anderson ME, et al. Safety of omitting routine bleeding tests prior to image-guided musculoskeletal core needle biopsy. Skelet Radiol. 2018;47:215–21.
Liu Y. Diagnostic role of fluorodeoxyglucose positron emission tomography-computed tomography in prostate cancer. Oncol Lett. 2014;7:2013–8.
Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51:1511–20 discussion 20-1.
Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996;199:751–6.
Budak E, Yanarates A. Role of (18)F-FDG PET/CT in the detection of primary malignancy in patients with bone metastasis of unknown origin. Rev Esp Med Nucl Imagen Mol. 2020;39:14–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Su Woong Yoo, Md. Sunny Anam Chowdhury, Subin Jeon, Sae-Ryung Kang, Changho Lee, Zeenat Jabin, Jahae Kim, Sang-Geon Cho, Ho-Chun Song, Hee-Seung Bom, Jung-Joon Min, and Seong Young Kwon declare that they have no conflict of interest.
This research was supported by a grant from KOICA, Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. NRF-2019M3E5D1A02067958), the National Research Foundation Korea (NRF) grants funded by the Korean government (MSIT) (No. NRF-2018R1D1A1B07050011).
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.
Informed Consent
The institutional review board of our institute approved this retrospective study, and the requirement to obtain informed consent was waived.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yoo, S.W., Chowdhury, M.S.A., Jeon, S. et al. Clinical Impact of F-18 FDG PET-CT on Biopsy Site Selection in Patients with Suspected Bone Metastasis of Unknown Primary Site. Nucl Med Mol Imaging 54, 192–198 (2020). https://doi.org/10.1007/s13139-020-00649-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13139-020-00649-4